mTOR inhibitors have also shown improvements in the other manifestations of TSC including renal angiomyolipomas, epilepsy, lymphangioleiomyomatosis, and facial angiofibromas (22–25). This evidence concerns the gene MTOR and kidney angiomyolipoma.